<DOC>
	<DOCNO>NCT00000843</DOCNO>
	<brief_summary>To evaluate single-dose pharmacokinetic profile acute toxicity bis-POM PMEA ( adefovir dipivoxil ) HIV-1 infected child , determine whether age-related difference exist . To ascertain dosage may suitable multiple-dose evaluation patient population . Although oral bioavailability PMEA ( adefovir ) low , prodrug bis-POM PMEA result increased bioavailability adult patient clinical trial . However , safety pharmacokinetic pattern drug infant often differ adult direction variation predictable . This study assess parameter bis-POM PMEA child .</brief_summary>
	<brief_title>The Safety Effectiveness Adefovir Dipivoxil HIV-Infected Children</brief_title>
	<detailed_description>Although oral bioavailability PMEA ( adefovir ) low , prodrug bis-POM PMEA result increased bioavailability adult patient clinical trial . However , safety pharmacokinetic pattern drug infant often differ adult direction variation predictable . This study assess parameter bis-POM PMEA child . Patients stratified age , separate cohort age group receive 1 2 single dos bis-POM PMEA . The low dose give patient age 3 month 17 year ; toxicity acceptable , cohort age range receive high dose . At point , accrual infant &lt; 3 month old may begin low dose , follow accrual age group high dose toxicity acceptable . Serum drug concentration monitor 8 hour post dose . AS PER AMENDMENT 5/2/97 : Based data low- high-dose cohort old age group ( &gt; = 3 month &lt; 18 year ) , young age group ( &lt; 3 month ) start high-dose .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Patients must : Asymptomatic mildly symptomatic HIV infection , bad grade 1 toxicity symptom . Consent parent guardian . Prior Medication : Allowed : IV gammaglobulin aerosolize pentamidine PCP prophylaxis . Antiretrovirals discontinue 72 hr prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute chronic infection require treatment study . Concurrent Medication : Excluded : Antiretrovirals study drug . Other investigational agent . Immunomodulators . HIV1 vaccine . Glucocorticoids . Drugs potential adverse interaction study drug would interfere quantitation study drug serum plasma . TMP / SMX dapsone . PER AMENDMENT 8/23/96 : Drugs may affect renal excretion : Probenecid , Acyclovir , Ganciclovir , Foscarnet , Amphotericin B Pentamidine . Prior Medication : Excluded within 72 hr prior study entry : Antiretrovirals study drug . Other investigational agent . Immunomodulators . HIV1 vaccine . Glucocorticoids . Drugs potential adverse interaction study drug would interfere quantitation study drug serum plasma . TMP / SMX dapsone . PER AMENDMENT 8/23/96 : Drugs may affect renal excretion : Probenecid , Acyclovir , Ganciclovir , Foscarnet , Amphotericin B Pentamidine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 1998</verification_date>
	<keyword>Antiviral Agents</keyword>
	<keyword>Adenine</keyword>
</DOC>